| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 10.25 | 0.51 | 3.31 | 7.16 | 11.88 | 9.15 | 11.49 | 1.04 | 2.33 | 1.55 | 2.71 | 4.32 |
| Quick Ratio | 10.25 | 0.51 | 3.31 | 7.16 | 11.88 | 9.15 | 11.49 | 1.04 | 2.33 | 1.55 | 2.71 | 4.32 |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE | -310.32% | 708.00% | -671.99% | -84.64% | -35.19% | -50.23% | -41.51% | -478.43% | -402.12% | -1290.14% | -417.20% | 180.04% |
| ROA | -269.64% | -817.51% | -270.39% | -70.05% | -31.60% | -41.84% | -32.88% | -115.39% | -132.33% | -129.69% | -266.83% | -263.92% |
| Asset Turnover | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
| Book Value / Share | 0.28 | -15.16 | 1.83 | 0.65 | 1.32 | 4.19 | 7.92 | 0.15 | 0.06 | 0.05 | — | — |
Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapies for chronic liver diseases. Its key asset, Rencofilstat, is a potent cyclophilin inhibitor aimed at treating conditions such as non-alcoholic steatohepatitis (NASH), liver fibrosis, and hepatocellular carcinoma (HCC). Rencofilstat targets multiple molecular pathways involved in liver disease progression, from initial triggers to those impairing liver function. The company leverages its AI-POWR platform for integrative bioinformatic analysis, utilizing both proprietary clinical data and public multi-omic databases to inform drug development. Recently, Hepion has transitioned towards developing and licensing diagnostic tests for diseases including celiac disease, respiratory infections, Helicobacter pylori, and HCC. Incorporated in 2013 and headquartered in Morristown, New Jersey, Hepion holds FDA Fast Track and Orphan Drug designations for Rencofilstat, reflecting its significance in addressing unmet medical needs in liver disease therapeutics.